⚗️ Metabolic Disorder

Glycogen Storage Disease

Also known as: GSD, Glycogenosis, Dextrinosis, Hepatorenal Glycogenosis, Forbes Disease, Cori Disease, Andersen Disease, McArdle Disease, Hers Disease, Tarui Disease, Fanconi-Bickel Syndrome

Glycogen storage disease (GSD) is a group of inherited metabolic disorders caused by defects in enzymes that regulate the synthesis or breakdown of glycogen. These defects lead to abnormal accumulation or deficiency of glycogen in various tissues, primarily the liver and muscles, resulting in a wide range of clinical manifestations depending on the specific enzyme deficiency.

👥 Approximately 1 in 20,000 to 40,000 live births Prevalence
🔬 35 Active Trials

Imagine your body has trouble storing and using sugar properly. Glycogen Storage Disease is when your body's sugar storage system doesn't work right, causing problems like low blood sugar and a big tummy because your liver gets too full.

Signs & Symptoms

  • Hepatomegaly (enlarged liver)
  • Hypoglycemia (low blood sugar)
  • Muscle weakness and cramps
  • Exercise intolerance
  • Growth retardation
  • Delayed motor development
  • Cardiomyopathy (heart muscle disease)
  • Kidney disease
  • Progressive liver disease (cirrhosis)
  • Elevated liver enzymes
  • Fatigue
  • Seizures

Treatment Options

SUPPORTIVE

Dietary Management (Frequent small meals, uncooked cornstarch)

HIGHLY EFFECTIVE
SUPPORTIVE

Glucose Monitoring

HIGHLY EFFECTIVE
ENZYME THERAPY FDA Approved

Enzyme Replacement Therapy (Myozyme for Pompe disease)

MODERATELY EFFECTIVE Approved 2006
SURGERY

Liver Transplantation

MODERATELY EFFECTIVE
GENE THERAPY

Gene Therapy

EXPERIMENTAL
SUPPORTIVE

Avoidance of Strenuous Exercise (McArdle Disease)

HIGHLY EFFECTIVE

Diagnosis

  • Physical examination and medical history
  • Blood tests (glucose, liver enzymes, creatine kinase)
  • Urine tests (ketones)
  • Muscle biopsy
  • Liver biopsy
  • Enzyme assays (to measure enzyme activity in tissues or blood)
  • Genetic testing (DNA sequencing to identify mutations in GSD-related genes)
  • Imaging studies (ultrasound, MRI) to assess liver and muscle involvement

History

The first description of glycogen storage disease was by von Gierke in 1929, who identified a patient with hepatomegaly and hypoglycemia due to a deficiency in glucose-6-phosphatase. Subsequent research led to the identification of other enzyme deficiencies involved in glycogen metabolism, leading to the classification of different types of GSD.

Recent Breakthroughs

2022

Advances in Gene Therapy for Glycogen Storage Disease Type Ia

Significant progress has been made in gene therapy approaches for GSD Ia, with early-phase clinical trials showing promising results in restoring glucose homeostasis and reducing the need for dietary management.

2023

Novel Enzyme Enhancer for Glycogen Storage Disease Type V (McArdle Disease)

Researchers have identified a small molecule enhancer that increases the activity of the deficient myophosphorylase enzyme in McArdle disease, potentially improving exercise tolerance and reducing muscle cramps.